The Cost‐Effectiveness of Rotavirus Vaccination in Malawi
Open Access
- 1 September 2010
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (1), S108-S115
- https://doi.org/10.1086/653578
Abstract
Background. Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands of lives in Africa. Nations such as Malawi, where Rotarix is currently under phase III investigation, may nevertheless face difficult economic choices in considering vaccine adoption. Methods. The cost-effectiveness of implementing a Rotarix vaccine program in Malawi was estimated using published estimates of rotavirus burden, vaccine efficacy, and health care utilization and costs. Results. With 49.5% vaccine efficacy, a Rotarix program could avert 2582 deaths annually. With GAVI Alliance cofinancing, adoption of Rotarix would be associated with a cost of $5.07 per disability-adjusted life-year averted. With market pricing, Rotarix would be associated with a base case cost of $74.73 per disability-adjusted life-year averted. Key variables influencing results were vaccine efficacy, under-2 rotavirus mortality, and program cost of administering each dose. Conclusions. Adopting Rotarix would likely be highly cost-effective for Malawi, particularly with GAVI support. This finding holds true across uncertainty ranges for key variables, including efficacy, for which data are becoming available.Keywords
This publication has 23 references indexed in Scilit:
- Epidemiology of rotavirus-associated hospital admissions in the province of Ferrara, ItalyEuropean Journal of Pediatrics, 2009
- Cost-effectiveness of three different vaccination strategies against measles in Zambian childrenVaccine, 2003
- Global Illness and Deaths Caused by Rotavirus Disease in ChildrenEmerging Infectious Diseases, 2003
- The World Health Report 2002 - Reducing Risks, Promoting Healthy LifePublished by Informa UK Limited ,2003
- Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian childrenThe Lancet, 2001
- Discounting for health effects in cost–benefit and cost‐effectiveness analysisHealth Economics, 2001
- Epidemiology and predictors of infant morbidity in rural MalawiPaediatric and Perinatal Epidemiology, 2000
- Discounting: technical issues in economic evaluations of vaccinationVaccine, 1999
- Rotavirus Infection in Infants as Protection against Subsequent InfectionsNew England Journal of Medicine, 1996
- Global progress in the control of diarrheal diseasesThe Pediatric Infectious Disease Journal, 1990